Bexagliflozin is primarily used in the management of type 2 diabetes mellitus. It works by inhibiting the sodium-glucose co-transporter 2 (SGLT2) in the kidneys, which helps to lower blood glucose levels by promoting the excretion of glucose through urine. This mechanism of action not only aids in controlling blood sugar but also contributes to weight loss and a reduction in blood pressure, making it beneficial for patients with diabetes who are overweight or have hypertension. Additionally, it has shown potential in reducing the risk of cardiovascular events in diabetic patients, providing a comprehensive approach to managing the disease and its associated complications.